Trem Rx unveils vaccine platform

Trem Rx Inc. (Boston, Mass.) made its public debut Thursday and unveiled its Trem Rx vaccine platform, which comprises engineered replication-deficient viruses that induce the production of T Resident Effector Memory cells (TREMs) in epithelial tissues. The vaccines are applied to an abraded upper layer of the skin rather than by injection into the muscles or bloodstream. The company plans to develop the platform for diseases such as respiratory syncytial virus (RSV), polio, influenza, tuberculosis, HIV/AIDS, cancers caused by HPV infection, and cancers of skin and other epithelial tissues. Trem Rx is led by President Eric Stromquist, formerly a partner at investment management firm Wellington Management Company. ...